DDInter1055 DDInter1117
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium glycinate
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium glycinate
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ergocalciferol
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium glycinate
Levofloxacin {u} (Compound) causes {v} (Side Effect) Urine output increased
Urine output increased {u} (Side Effect) is caused by {v} (Compound) Ergocalciferol
Ergocalciferol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium glycinate
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) is palliated by {v} (Compound) Doxycycline
Doxycycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium glycinate
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ergocalciferol (Compound) and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Levofloxacin (Compound) causes Urine output increased (Side Effect) and Urine output increased (Side Effect) is caused by Ergocalciferol (Compound) and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is palliated by Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate